Engineered immune cells take aim at rare bone and soft tissue cancers
NCT ID NCT05621668
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new treatment called Attil12-T cell therapy for people with advanced soft tissue or bone sarcoma that has spread or cannot be removed. The therapy uses a patient's own immune cells, modified to target and attack the tumor. The main goals are to find a safe dose and see if it can help control the cancer. About 40 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Could a massive tissue bank unlock sarcoma's secrets?
- Can a targeted pill stall advanced sarcomas?
- Smartwatch exercise plan aims to rebuild fitness in young cancer survivors
- Can two drugs together fight Hard-to-Treat bone and Soft-Tissue cancers?